parkinson's disease models - preclinical services

proposal-button

talk-scientist

toolbox

read-blog

pd-whitepaper

Preclinical efficacy testing in models of Parkinson's Disease

Parkinson's Disease

Parkinon's Disease (PD) is a neurogenerative disorder characterized by reduction in striatial (DA) content caused by the loss of dopaminergenic neurons in the Substantia Nigra part compacta (SNpc) and their proportions to the striatum. Several neurotoxins induced PD-like neuropathology, includeing the neurotoxins 6-hydroxydopamine (6OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). These models mimic the depletion in dopaminergic (DAmergic) cells.

MD Biosciences offers pre clinical contract research services for the following PD models:

PD Model Description Length
Acute MPTP-induced PD MPTP is an effective dopaminergic neurotoxin that selectively destroys dopamine neurons in the substantia nigra, resulting in a Parkinson's-like syndrome.
7 days
6-OHDA The 6OHDA induced model is a unilateral lesion model of which the Nigro-Striatial pathway is damaged.
15 days